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Abstract
Antibodies against cyclic citrullinated peptide (CCP) and
rheumatoid factors (RFs) have been demonstrated to predate
the onset of rheumatoid arthritis (RA) by years. A nested case–
control study was performed within the Northern Sweden
Health and Disease study cohort to analyse the presence of
shared epitope (SE) genes, defined as HLA-DRB1*0404 or
DRB1*0401, and of anti-CCP antibodies and RFs in individuals
who subsequently developed RA. Patients with RA were
identified from among blood donors whose samples had been
collected years before the onset of symptoms. Controls
matched for age, sex, and date of sampling were selected
randomly from the same cohort. The SE genes were identified
by polymerase chain reaction sequence-specific primers. Anti-
CCP2 antibodies and RFs were determined using enzyme
immunoassays. Fifty-nine individuals with RA were identified as
blood donors, with a median antedating time of 2.0 years
(interquartile range 0.9–3.9 years) before presenting with
symptoms of RA. The sensitivity for SE as a diagnostic indicator
for RA was 60% and the specificity was 64%. The
corresponding figures for anti-CCP antibodies were 37% and
98%, and for RFs, 17–42% and 94%, respectively. In a logistic
regression analysis, SE (odds ratio [OR] = 2.35), anti-CCP
antibodies (OR = 15.9), and IgA-RF (OR = 6.8) significantly
predicted RA. In a combination model analysis, anti-CCP
antibodies combined with SE had the highest OR (66.8, 95%
confidence interval 8.3–539.4) in predicting RA, compared with
anti-CCP antibodies without SE (OR = 25.01, 95% confidence
interval 2.8–222.2) or SE without anti-CCP antibodies (OR =
1.9, 95% confidence interval 0.9–4.2). This study showed that
the presence of anti-CCP antibodies together with SE gene
carriage is associated with a very high relative risk for future
development of RA.
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Introduction
Autoimmune diseases, such as rheumatoid arthritis (RA),
are believed to develop as a result of dysregulation of the
immune system, leading ultimately, in RA, to the clinical fea-
tures of inflammation and destruction in several joints [1].
The aetiology of RA has been suggested to be an interac-
tion between genetic and environmental factors. To date, it
has not been possible to identify individuals at early stages
of this dysregulation, i.e. before presentation with clinically
obvious polyarthritis. If methods were available to predict
future development of RA, a better understanding of the
events triggering the disease would be achieved, thereby
creating the possibility of developing and testing preventive
measures and of instituting therapy at earlier stages of dis-
ease development than is current practice.
Previous studies have demonstrated that the presence of
rheumatoid factors (RFs) of IgM, IgG, and IgA class [2,3]
CCP = cyclic citrullinated peptide; CI = confidence interval; IQR = interquartile range; NSHDS = Northern Sweden Health and Disease Study; OR 
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predict the development of rheumatoid arthritis and in a
case–control study we found that antibodies against cyclic
citrullinated peptide (CCP), as well as RFs, predated the
onset of RA by several years [3]. Both anti-CCP antibodies
and IgA-RF predicted the development of RA, with the
highest predictive value for anti-CCP antibodies, indicating
that citrullination and production of anti-CCP antibodies
and RF are early processes in the development of RA [3].
The HLA-DRB1 locus has been shown to be linked to and
associated with RA, with an especially high risk in individu-
als with compound heterozygosity for shared epitope (SE)
genes [4]. However, there are no previous reports of stud-
ies combining serological and genetic factors in order to
optimise the prediction of a future risk of developing RA. In
the present study, we have evaluated the significance of
the presence of SE genes, defined as DRB1*0404 or
DRB1*0401, in relation to anti-CCP antibodies and RFs in
individuals who subsequently developed RA.
Materials and methods
Subjects
A nested case–control study was performed within the
Northern Sweden Health and Disease Study (NSHDS) and
the Maternity cohort of Northern Sweden. All adult individ-
uals of the county of Västerbotten were invited to partici-
pate; consequently, the cohorts are population-based and
no individual was excluded. The NDHDS cohort consists of
three subcohorts, which, together with conditions for
recruitment into the cohorts and the collection and storage
of blood samples, have previously been described in detail
[3]. The registry of patients who fulfilled the American Col-
lege of Rheumatology classification criteria for RA [1] and
who attended the Department of Rheumatology, University
Hospital, Umeå (the only medical centre for rheumatology
in the county of Västerbotten), and with a known date of
onset of symptoms or signs of joint disease, was coana-
lysed with the registers of the cohorts from the Blood Bank
for Västerbotten located in Umeå. At the time of the study,
the median duration of disease since the diagnosis of RA
was 3.0 years (interquartile range [IQR] 1.8–5.8 years).
Eighty-six individuals were identified from the cohorts as
having donated blood samples before the onset of symp-
toms or signs of joint disease. Samples from three individ-
uals were not available. Of the remaining 83 individuals
(referred to here as 'prepatients'), blood samples for DNA
analysis were available only from the NSHDS cohort, result-
ing in 59 prepatients (45 women and 14 men); the Mater-
nity cohort did not include collection of samples for DNA
analysis. Power calculations showed that two controls per
patient would be sufficient, based on pretest probability of
our previous results of HLA-DR4 frequencies in patients
and controls from this area [5]. Therefore, we selected for
genetic analysis two controls (out of the four who were pre-
viously analysed for antibody titres [3]) for every prepatient.
The controls were randomly selected from the same subco-
horts as the original cases within the NSHDS cohort and
matched for sex, for age at the time of blood sampling, and
for area of residence (rural or urban). The mean age of the
prepatients at the time of blood sampling was 53 years
(range 31–67 years) and of the controls, 53 years (range
30–67 years). The median sampling time before onset of
symptoms of joint disease was 2.0 years (IQR 0.9–3.9
years). The antedating time for the samples was calculated
to the onset of any symptoms of RA in all prepatients. Addi-
tional samples were collected from the prepatients at their
first visit to the early-arthritis clinic (n = 52), i.e. when RA
was diagnosed. On average, the diagnosis of RA was
established 7.1 ± 2.8 (SD) months after the first symptoms
of joint disease. The mean age at the onset of disease was
56.6 years, range 34–68 years. The Ethics Committee
approved this study at the University Hospital, Umeå, and
the blood donors to the Blood Bank had given their written
informed consent.
HLA-DRB1 genotyping was performed using polymerase
chain reaction sequence-specific primers from DR low-res-
olution kit and DRB1*04 subtyping kit (Olerup SSP AB,
Saltsjöbaden, Sweden). The SE genes were defined as
DRB1*0404 and DRB1*0401. Samples for DNA analysis
from one prepatient and three controls were not available,
and HLA typing of one prepatient and two controls was
unsuccessful. Consequently, results of HLA typing were
available from 57 prepatients and 112 controls.
The anti-CCP2 (Mark2) antibodies and the RFs were deter-
mined using enzyme-linked immunoassays as previously
described [3].
Statistical analysis
The chi-square test was used for testing differences in fre-
quencies of categorical data between groups. The sensitiv-
ity and specificity of SE gene carriage both separately and
in combination with anti-CCP antibodies and RFs were cal-
culated. Logistic regression analyses were used to esti-
mate the odds ratio (OR) for the presence of SE gene
carriage separately and in combination with anti-CCP anti-
bodies or RFs as predictors for RA. The OR was calculated
with 95% confidence intervals (CI). All P values are two-
sided, and P values equal to or less than 0.05 were consid-
ered statistically significant. The calculations were per-
formed using the SPSS package for Windows (version
11.0; SPSS, Chicago, IL, USA).
Results
The sensitivity found for the presence of SE genes as a
diagnostic indicator for RA in prepatients was 60% (34/57)
and the specificity was 64% (Table 1). The respective fig-
ures for carriers of two SE genes were 28% (16/57) and
95%. The specificity for the allele B1*0401 (74%) was
higher than that for SE given either B1*0401 or B1*0404Available online http://arthritis-research.com/content/6/4/R303
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(data not shown). The frequencies of the presence of one
or both of the SE genes studied in the prepatients were sig-
nificantly greater than in the controls (P = 0.003 and P =
0.0001, respectively). Of the prepatients, 37% (22/59)
tested positive for anti-CCP-antibodies, with a specificity of
98%. The sensitivity for IgA-RF was 42% (25/59), for IgM-
RF 22% (13/59), and for IgG-RF 17% (10/59) (Table 1).
The specificity was 94% for all three RF isotypes. The com-
bination of SE gene carriage and anti-CCP antibodies
increased the specificity to 99%, as did the combination of
SE genes and IgG-RF (Table 1). The presence of double
doses of the SE genes studied, in combination with either
anti-CCP-antibodies, IgA-RF, or IgM-RF, gave a specificity
of 99%, and, in combination with IgG-RF, of 100% (Table
1).
In a univariate logistic regression model, SE gene carriage,
and particularly carriage of two SE alleles, significantly pre-
dicted RA (OR = 2.66, 95%CI 1.38–5.12 and OR = 6.89,
95%CI 2.52–18.84, respectively). In multivariate models
including anti-CCP antibodies and RFs of all isotypes, sin-
gle or double SE gene carriage significantly predicted RA
in addition to our previously described predictive value of
anti-CCP antibodies and IgA-RF [3]. The OR for SE gene
carriage was 2.35 (95%CI 1.05–5.26) and for double SE
gene carriage 7.31 (95%CI 2.26–23.67) (data not shown).
In a univariate logistic regression analysis, the combination
of anti-CCP antibodies and SE gene carriage gave an OR
of 66.8, while the presence of anti-CCP-antibodies alone
gave an OR of 25.1 for the risk of developing RA compared
with not having any of these factors (Table 2). The calcula-
tion on the SE allele B1*0401 selectively in the same model
gave essentially the same results (data not shown). Further-
more, in the same type of analysis, SE gene carriage and
IgA-RF showed similar results but at a lower level (Table 2).
However, in the analysis including IgM-RF and SE, only SE
gene carriage separately or in combination with IgM-RF sig-
nificantly predicted RA; the same pattern was found for
combinations of IgG-RF and SE (Table 2).
Except for a borderline significant association between the
SE allele B1*0401 and anti-CCP-antibodies (P = 0.051),
no significant association between SE gene carriage and
the expression of anti-CCP-antibodies or RFs could be
demonstrated (data not shown). As previously reported [3],
anti-CCP antibodies and RFs were associated (data not
shown).
When the prepatients were diagnosed after having devel-
oped RA, the sensitivity for anti-CCP antibodies was 71%,
for IgG-RF 45%, for IgM-RF 73%, and for IgA-RF 71%. As
regards SE, a significant association was found only
between the presence of anti-CCP antibodies and
B1*0401 (P = 0.027), and not between SE and any of the
RFs.
Discussion
This study shows a greatly increased OR for the develop-
ment of RA in individuals with the combination of SE gene
carriage and anti-CCP antibodies or an RF of any isotype,
in comparison with individuals not having any of the factors
or having any one of them separately. In particular, the com-
bination of SE gene carriage and the presence of anti-CCP
antibodies appeared to be prognostic for the future
development of RA. Previous studies by us [3] and others
[2] have demonstrated that an increased production of
autoantibodies may precede the development of RA. How-
ever, this is the first report in which autoantibody analyses
have been combined with genotyping to show a remarkably
high predictive value for the future development of RA. The
main methodological strength of the current study is that
the blood sampling of individuals who later developed RA
and their controls was population based.
The results do not support the notion that there is a direct
association between SE gene carriage and the occurrence
of antibodies directed to CCP (or RFs) leading to the devel-
Table 1
Sensitivity and specificity as diagnostic indicators for 
rheumatoid arthritis for antibodies against cyclic citrullinated 
peptide (anti-CCP Ab) and for rheumatoid factor (RF) of IgA, 
IgM, and IgG isotypes, in combination with the presence of a 
shared epitope (SE) allele – HLA-DRB1*0401 or B1*0404 – in 59 
'prepatients' whose blood samples antedated the appearance 
of symptoms of rheumatoid arthritis (median 2.0 years 
[interquartile range 0.9–3.9]) and in 118 matched controls.
Variables Sensitivity Specificity
% 95%CI % 95%CI
Anti-CCP Ab 37 25–51 98 93–100
IgA-RF 42 29–56 94 87–98
IgM-RF 22 12–35 94 87–98
IgG-RF 17 8–30 94 87–98
SE (B1*0404 or 0401)1 60 45–72 64 54–73
SE + anti-CCP Ab 28 17–42 99 94–100
SE + IgA-RF 25 14–38 98 93–100
SE + IgM-RF 14 6–27 98 93–100
SE + IgG-RF 11 4–22 99 94–100
SESE (B1*0404 or 0401)1 28 17–42 95 88–98
SESE + anti-CCP Ab 14 6–27 99 94–100
SESE + IgA-RF 7 2–18 99 94–100
SESE + IgM-RF 5 1–16 99 94–100
SESE + IgG-RF 4 0–14 100 95–100
1Analysed in 57 prepatients and in 112 controls. CI, confidence 
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opment of RA, but rather suggest that there is a synergistic
interaction between these factors. Our knowledge about
what triggers the production of anti-CCP antibodies in
healthy individuals is limited, as is the role of SE genes in
this context. The conversion of arginine to citrulline in HLA-
DRB1*0401 transgenic mice has been demonstrated to
significantly increase activation of CD4+ T cells [6]. In a pre-
vious study of patients with early RA, a significant associa-
tion between anti-CCP antibodies and expression of
B1*0401/0101 was reported [7]. This finding suggests
that individuals carrying the SE genes may have more sus-
tained T- and B-cell responses to citrullinated antigens than
noncarriers. Taken together, these data suggest that in indi-
viduals carrying one or two SE genes, a specific T-cell-
dependent immune response to citrullinated peptides may
contribute to the occurrence of RA. In the prepatient
cohort, there appeared to be a weak association, with bor-
derline statistical significance, between the presence of
anti-CCP antibodies and B1*0401. This association was
strengthened when the prepatients had developed RA and
when the number of individuals with anti-CCP antibodies
had increased. However, there does not seem to be an
absolute requirement for SE genes to develop anti-CCP
antibodies [8]. The ORs for predicting RA were high for
anti-CCP antibodies and for RFs but comparatively low for
SE gene carriage. The overriding reason for this difference
is the relatively high frequency among controls of the SE
gene, which is also evident from the relatively low specifi-
city of SE gene carriage in the prepatients.
A quite contradictory suggestion is that HLA antigens do
not predispose to the autoimmune disease per se but
rather fail to provide protection. Abnormal T-cell regulation
associated with certain HLA haplotypes leads to the loss of
self-tolerance followed by polyclonal activation of T and B
cells and the subsequent production of autoantibodies [9].
This mechanism could be applicable to autoantibodies
assessed in this study and would, therefore, explain the
findings.
In a recent report on the genetic control of RF production
in a rat model of RA, it was shown that the antibody
response is controlled by several other genetic regions in
addition to the defined arthritis loci [10]. The strength of the
genetic association between HLA-DR4 and RA is reported
to vary according to disease severity and the population
studied [11]. The HLA gene locus has been calculated to
contribute to one-third of the genetic risk for developing RA
[12,13]. It is, therefore, apparent that other, non-HLA linked
genes contribute to the risk of RA [14]. Two recent reports
presented numerous single-nucleotide polymorphisms in
the peptidyl arginine deiminase enzyme 4, i.e. the enzyme
Table 2
Results of logistic regression analyses of anti-CCP antibodies (anti-CCP Ab) or rheumatoid factor (RF) of IgG, IgM, or IgA isotype 
and shared epitope (SE) in predicting rheumatoid arthritis, analysed in individuals who later developed the disease and in controls.
Combinations of variables Patients (no.) Controls (no.) OR 95%CI
SE- and anti-CCP Ab- 17 71 1.0
SE+ and anti-CCP Ab- 18 39 1.9 0.9–4.2
SE- and anti-CCP Ab+ 6 1 25.1 2.8–222.2
SE+ and anti-CCP Ab+ 16 1 66.8 8.3–539.4
SE- and IgA-RF- 12 67 1.0
SE+ and IgA-RF- 20 38 2.9 1.3–6.7
SE- and IgA-RF+ 11 5 12.3 3.6–41.7
SE+ and IgA-RF+ 14 2 39.2 7.9–193.9
SE- and IgM-RF- 18 71 1.0
SE+ and IgM-RF- 26 38 2.6 1.2–5.2
SE- and IgM-RF+ 5 5 3.7 0.99–14.3
SE+ and IgM-RF+ 8 2 14.9 2.9–76.3
SE- and IgG-RF- 19 67 1.0
SE+ and IgG-RF- 28 39 2.5 1.3–5.1
SE- and IgG-RF+ 4 5 2.8 0.7–11.6
SE+ and IgG-RF+ 6 1 21.2 2.4–186.5
CI, confidence interval; OR odds ratio.Available online http://arthritis-research.com/content/6/4/R303
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converting peptidylarginine to peptidylcitrulline, several of
which are strongly associated with RA [15,16]. Carriers of
the susceptibility haplotype had antibodies against citrulli-
nated proteins significantly more often than noncarriers
[15,16].
The limitation of this study is the sample size, which
resulted in a relatively low number of individuals in each
group when the data were stratified for individuals positive
or negative for a given antibody. Furthermore, we empha-
sise that this is a population-based case–control study,
which makes it possible to establish associations between
the outcome and the factors studied but precludes calcula-
tion of the probability of being a case, given certain values
on the analysed factors. In this study, calculations are
based on the combination of SE and the analysed autoan-
tibodies. This is because anti-CCP antibodies and RFs are
significantly associated, and consequently prediction of RA
is only marginally increased when they are considered in
combination.
Conclusion
This study has demonstrated that the presence of anti-CCP
antibodies together with SE gene carriage is associated
with a very high relative risk for future development of RA.
This strong association with future development of RA in
individuals positive for both SE and anti-CCP antibodies
poses important questions relating to ethics and health pol-
icy. Thus, we shall need new strategies, both in research
intended to understand factors that determine whether an
individual with the presently identified risk factors will
develop RA, and in clinical practice, where we may now
possess a new means for analysing the risk of future devel-
opment of RA in individuals who will have different needs or
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